Barr announces management changes
-
- March
- 28
Bruce L. Downey, chairman and chief executive officer of Barr Pharmaceuticals Inc., will turn over much of the day-to-day management to newly appointed heads of the company’s operating businesses in a major management restructuring.
Barr, a drug manufacturer which has major operations in Rockland County, said that Downey will keep his current poitions but spend more time on strategic responsibilities. As part of the changes, Barr named CEOs to oversee its generic drug and branded pharmaceutical businesses.
“The senior management team at Barr has long been recognized internally and externally as among the most talented in the industry, and their individual and collective contributions are critical to our success in the specialty pharmaceuticals sector,” Downey said in a written statement. “Today, I am pleased to elevate these key executives to additional significant areas of responsibility…”
Christine Mundkur was named CEO of Barr Laboratories Inc., the company’s generic pharmaceutical business. Since joining the company in 1993, she has held various management jobs. Her most recent assignment was executive vice president of global quality, safety and regulatory affairs. During 2007, she worked at the company’s European headquarters in Croatia.
Barr, based in Montvale, N.J., also named Fred Wilkinson as the CEO of Duramed Pharmaceuticals, the company’s proprietary products business. Wilkinson, who joined Barr in 2006, has more than 25 years of experience in the industry. His prior jobs include serving as CEO of Columbia Laboratories and working as chief operating officer and senior vice president at Watson Pharmaceuticals.
In other changes, Mike Bogda was named president and chief operating officer of Barr Laboratories; Timothy Sawyer was named executive vice president, global generic sales and marketing, of Barr Laboratories; and Bill McKee, executive vice president and chief financial officer of Barr Pharmaceuticals, will assume an expanded role.









